InMed Pharmaceuticals Inc. (MWG0.F)

0,2240 -0,0155 (-6,47 %) À partir de 08:12AM CEST. Marché ouvert.

InMed Pharmaceuticals Inc.

815 West Hastings Street
Suite 310
Vancouver, BC V6C 1B4
Canada
604 669 7207
https://www.inmedpharma.com

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 13

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Mr. Eric A. Adams B.S. Chem., M.I.B.	President, CEO & Director	324,09k	S.O.	1963
Mr. Michael Woudenberg P.Eng.	Chief Operating Officer	267,93k	S.O.	1969
Ms. Alexandra Diane-Janet Mancini M.Sc.	Senior Vice President of Clinical & Regulatory Affairs	260,33k	S.O.	1953
Dr. Sazzad Hossain M.Sc., Ph.D.	Co-Founder	126k	S.O.	1958
Ms. N. Netta Jagpal	CFO & Corporate Secretary	S.O.	S.O.	1973
Ms. Sarah Li CPA, CGA	VP of Accounting & Controller	S.O.	S.O.	S.O.
Colin Clancy	Senior Director of Investor Relations	S.O.	S.O.	S.O.
Mr. Jerry P. Griffin	Vice President of Sales & Marketing	S.O.	S.O.	S.O.
Dr. Eric Chih-Hsien Hsu	Senior Vice President of Preclinical Research & Development	236,17k	S.O.	1970
Dr. Shane A. Johnson Ph.D.	Senior VP & GM of BayMedica	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en EUR.

Description

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Gouvernance d’entreprise

L’ISS Governance QualityScore de InMed Pharmaceuticals Inc. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.